Information  X 
Enter a valid email address

SkinBioTherapeutics (SBTX)


Wednesday 27 April, 2022


Confirmation of Directorate Appointments

RNS Number : 4394J
SkinBioTherapeutics PLC
27 April 2022

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Confirmation of Directorate Appointments

27 April 2022 - SkinBioTherapeutics plc (AIM: SBTX), a life Science business focusing on skin health, today announces that further to the announcement of 28 March 2022, the proposed appointments of Manprit Singh Randhawa as full time Chief Financial Officer (CFO) and Danielle Bekker as non-executive director have been approved by the Company's AIM Nominated Adviser.

Danielle Bekker will commence in the role of non-executive director immediately while Manprit Randhawa will commence his appointment by 1 June 2022. Doug Quinn will continue as CFO until Manprit is appointed, stepping down from the board with effect 1 May 2022.


Manprit Singh Randhawa, aged 39, holds or has held in the past 5 years the following directorships and partnerships:



Past five years

Juniper Education Group Limited

Juniper Education Holdco Limited

Juniper Education Holdings Limited

Juniper Education Limited

Juniper Education Midco Limited

Juniper Education Services Limited

Klik Limited

Maze Education Limited

Optimum Reports Ltd

Prime Principle Limited

Pupilasset Ltd

Target Tracker Limited

Financial Services 4 Schools Limited

The Concentric Curriculum Limited

Sisra Limited

Juniper Education Newco Limited

Jane IT Systems Limited

Primarysite Limited

E4Education Limited

E4Education Holdings Limited

Bidco Oasis Limited

Oval (2304) Limited

Smoothwall Limited

Topco Oasis Limited

Safeguard Software Limited

Onbone Sports Limited

Onbone Ltd


Danielle Bekker, aged 45, holds or has held in the past 5 years the following directorships and partnerships:



Past five years

Good Living Brew Co Limited

Marmalade Consulting Limited

Flexipro Employee Resources (Pty) Ltd



Save as disclosed above, no further information is required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.


For more information please contact:

SkinBioTherapeutics plc

Stuart J . Ashman, CEO

Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson, Dale Bellis (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Tim Field / Jonjo Cordey

Tel: +44 (0) 20 7457 2020

[email protected]



About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: .



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t